These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10895129)

  • 1. Progress in the management of metastatic bladder cancer.
    Parimoo D; Raghavan D
    Cancer Control; 2000; 7(4):347-56. PubMed ID: 10895129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
    Roberts JT; von der Maase H; Sengeløv L; Conte PF; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
    Ann Oncol; 2006 May; 17 Suppl 5():v118-22. PubMed ID: 16807438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
    Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis.
    Yu C; Hequn C; Jinbo C; Feng Z; Xiongbing Z; Jian D
    J Cancer Res Ther; 2018; 14(6):1260-1265. PubMed ID: 30488841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The present and future of combination chemotherapy in bladder cancer.
    Culine S
    Semin Oncol; 2002 Jun; 29(3 Suppl 9):32-9. PubMed ID: 12094336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of metastatic bladder cancer].
    Gauthier H; Serrate C; Pouessel D; Le Maignan C; Teixeira L; Culine S
    Rev Prat; 2014 Dec; 64(10):1405-7. PubMed ID: 25668832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
    Miller RS; Torti FM
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
    Sternberg CN; de Mulder PH; Schornagel JH; Théodore C; Fossa SD; van Oosterom AT; Witjes F; Spina M; van Groeningen CJ; de Balincourt C; Collette L;
    J Clin Oncol; 2001 May; 19(10):2638-46. PubMed ID: 11352955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
    Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].
    Fukuda H; Mitsumori K; Minagawa S; Kumazawa T; Tadachi K; Iinuma M; Satoh S; Satoh K; Habuchi T; Kato T
    Hinyokika Kiyo; 2005 Feb; 51(2):113-6. PubMed ID: 15773365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.
    Yin M; Joshi M; Meijer RP; Glantz M; Holder S; Harvey HA; Kaag M; Fransen van de Putte EE; Horenblas S; Drabick JJ
    Oncologist; 2016 Jun; 21(6):708-15. PubMed ID: 27053504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New developments in chemotherapy for metastasized bladder cancer].
    de Wit R
    Ned Tijdschr Geneeskd; 2001 Dec; 145(50):2412-7. PubMed ID: 11776665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].
    Kawamura N; Matsushita M; Okada T; Ujike T; Nin M; Tsujihata M
    Hinyokika Kiyo; 2013 May; 59(5):277-81. PubMed ID: 23719134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New chemotherapy regimens for advanced bladder cancer.
    Fagbemi SO; Stadler WM
    Semin Urol Oncol; 1998 Feb; 16(1):23-9. PubMed ID: 9508079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
    Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of metastatic small cell carcinoma of the bladder with methotrexate, vinblastine, doxorubicin and cisplatin therapy.
    Cheng DL; Unger P; Forscher CA; Fine EM
    J Urol; 1995 Feb; 153(2):417-9. PubMed ID: 7815604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.